National Cancer Center Network guidelines propose molecular profiling for patients with unresectable or metastatic biliary tract cancer as a routine workup before initiating first-line chemotherapy and three molecular markers (MSI-H, NTRK fusion, and RET fusion) and matched therapies are now recommended as a treatment option of first-line chemotherapy [21]. This evidence concerns the gene RET and biliary tract cancer.